ITeos Therapeutics Inc (NAS:ITOS)

$ 8.34 -0.21 (-2.46%) Market Cap: 304.69 Mil Enterprise Value: -170.82 Mil PE Ratio: 0 PB Ratio: 0.48 GF Score: 46/100

Iteos Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Iteos Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 27, 2023
Iteos Therapeutics Inc at Cowen Health Care Conference Transcript
Mar 07, 2023
Iteos Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Iteos Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Iteos Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Q3 2021 Iteos Therapeutics Inc Earnings Call Transcript
Nov 10, 2021

$29.43 (+0.38%)

Earnings
Q2 2021 Iteos Therapeutics Inc Earnings Call Transcript
Aug 12, 2021

$24.91 (-0.44%)

Earnings
Iteos Therapeutics Inc to Discuss Collaboration with GlaxoSmithKline PLC for EOS-448 Call Transcript
Jun 14, 2021
Iteos Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021

Iteos Therapeutics Inc to Discuss Collaboration with GlaxoSmithKline PLC for EOS-448 Call Transcript

Jun 14, 2021 / 12:30PM GMT

Release Date Price: $27.5 (+37.29%)

Transcript

Operator

Good morning, and welcome to the iTeos Therapeutics Business Update Conference Call. (Operator Instructions) Please be advised this call is being recorded at the company's request.

At this time, I'd like to turn it over to Ryan Baker, Head of Investor Relations at iTeos.

Ryan Baker

iTeos Therapeutics, Inc. - Head of IR

Thank you for joining us today. Joining me from iTeos are Michel Detheux, President and CEO; Matthew Gall, Chief Financial Officer; Matt Call, Chief Operating Officer; and Dr. Jo Lager, Chief Medical Officer. This morning, iTeos issued a news release announcing that it has entered into a partnership with GlaxoSmithKline to co-develop and co-commercialize iTeos' anti-TIGIT antibody, EOS-448, as a potential treatment for people with cancer.

Before I turn the call over to Michel to discuss the details of the partnership, I would like to note that the team will be making forward-looking statements in the prepared remarks and during the Q&A session. Please take a moment to review Slide #2 on the webcast, which contains our

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.